NDLI: Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

Please wait, while we are loading the content...

Volume 13, 2018

Volume 12, 2017

Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability

Public health implications of milk fats: the current evidence base and future directions

Alirocumab: an investigational treatment for hypercholesterolemia

The National Lipid Association’s new recommendations for patient-centered management of cholesterol

The appropriate clinical use of niacin in the treatment of dyslipidemia

Understanding adipocyte types and adipose tissue dynamics for obesity management

Why are there inconsistencies in the outcomes of some omega-3 fatty acid trials for the management of cardiovascular disease?

Twenty-five years of statins: where do we go from here?

Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

High-density lipoproteins at the interface between central nervous system and plasma lipoprotein metabolism

Novel method for reducing plasma cholesterol: a ligand replacement therapy

Challenges to determining whether DHA can protect against age-related cognitive decline

Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors

Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

Content Provider	Taylor & Francis Online
Author	Asimakopoulou, Anastasia Weiskirchen, Ralf
Abstract	The lipocalins were originally classified as a widespread group of transport proteins for small hydrophobic molecules. Although they only share a limited sequence homology their 3D fold is conserved. This group of proteins has been implicated in a multitude of biological processes that most often become visible during disease formation. Lipocalin 2 (LCN2) serves as a siderocalin and protects against bacterial infections. In the liver, LCN2 expression is upregulated during inflammation and in response to cellular stress evolving protective effects during acute and chronic injury. LCN2 was shown to act as an adipokine in the pathogenesis of nonalcoholic fatty liver disease and in control of brown adipose tissue activation. In a nutritional model of nonalcoholic steatohepatitis, LCN2 was identified as a key factor that controls the expression of the perlipin 5 regulating cellular lipid droplet formation. We here summarize experimental and clinical findings linking LCN2 to fatty liver disease.
Starting Page	47
Ending Page	67
Page Count	21
File Format	PDF HTM / HTML
ISSN	17584299 17584302
Journal	Clinical Lipidology
Volume Number	10
Issue Number	1
DOI	10.2217/clp.14.65
Language	English
Publisher	Taylor & Francis
Publisher Date	2017-01-18
Access Restriction	Open
Subject Keyword	FABP Fatty liver disease Insulin resistance LCN2 Lipocalin NASH NF-κB NGAL OXPAT Perlipin PLIN5 RBP
Content Type	Text
Subject	Endocrinology, Diabetes and Metabolism Cardiology and Cardiovascular Medicine

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)

A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease

Intrauterine Growth Retardation, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in Children

Review: Advances in the treatment of nonalcoholic fatty liver disease

The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Therapeutic approaches for non-alcoholic steatohepatitis

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis

Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis

Similar Documents

An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)

A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease

Intrauterine Growth Retardation, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in Children

Review: Advances in the treatment of nonalcoholic fatty liver disease

The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease and Type 2 diabetes mellitus

Therapeutic approaches for non-alcoholic steatohepatitis

Role of Neutrophils in the Pathogenesis of Nonalcoholic Steatohepatitis

Insulin resistance in development and progression of nonalcoholic fatty liver disease.

Lipocalin 2 in the pathogenesis of fatty liver disease and nonalcoholic steatohepatitis